Immunoinformatics lessons on the current COVID-19 pandemic and future coronavirus zoonoses.
作者信息
López Daniel, García-Peydró Marina
机构信息
Presentation and Immune Regulation Unit, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda, Spain.
Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas (CSIC) - Universidad Autónoma de Madrid (UAM), Madrid, Spain.
出版信息
Front Immunol. 2023 Dec 12;14:1118267. doi: 10.3389/fimmu.2023.1118267. eCollection 2023.
Abstract
摘要
相似文献
1
Immunoinformatics lessons on the current COVID-19 pandemic and future coronavirus zoonoses.关于当前新冠疫情及未来冠状病毒人畜共患病的免疫信息学经验教训。
Front Immunol. 2023 Dec 12;14:1118267. doi: 10.3389/fimmu.2023.1118267. eCollection 2023.
2
A survey of ORF8 sequence and immunoinformatics features during alpha, delta, and wild type peaks of the SARS-CoV-2 pandemic in Iran.伊朗 SARS-CoV-2 大流行期间阿尔法、德尔塔和野生型高峰期间 ORF8 序列和免疫信息学特征的调查。
Malawi Med J. 2023 Jun;35(2):101-105. doi: 10.4314/mmj.v35i2.5.
3
Immunoinformatics-guided designing of epitope-based subunit vaccines against the SARS Coronavirus-2 (SARS-CoV-2).基于免疫信息学设计针对严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 的基于表位的亚单位疫苗。
Immunobiology. 2020 May;225(3):151955. doi: 10.1016/j.imbio.2020.151955. Epub 2020 May 11.
4
Reverse vaccinology assisted designing of multiepitope-based subunit vaccine against SARS-CoV-2.基于反向疫苗学的 SARS-CoV-2 多表位亚单位疫苗设计。
Infect Dis Poverty. 2020 Sep 16;9(1):132. doi: 10.1186/s40249-020-00752-w.
5
A Proteome-Wide Immunoinformatics Tool to Accelerate T-Cell Epitope Discovery and Vaccine Design in the Context of Emerging Infectious Diseases: An Ethnicity-Oriented Approach.一种基于蛋白质组学的免疫信息学工具，用于加速新兴传染病背景下的 T 细胞表位发现和疫苗设计：一种面向种族的方法。
Front Immunol. 2021 Feb 26;12:598778. doi: 10.3389/fimmu.2021.598778. eCollection 2021.
6
Transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to animals: an updated review.动物中严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）的传播：最新综述。
J Transl Med. 2020 Sep 21;18(1):358. doi: 10.1186/s12967-020-02534-2.
7
SARS-CoV-2 jumping the species barrier: Zoonotic lessons from SARS, MERS and recent advances to combat this pandemic virus.SARS-CoV-2 跨越物种屏障：SARS、MERS 带来的人畜共患病教训及应对此次大流行病毒的最新进展。
Travel Med Infect Dis. 2020 Sep-Oct;37:101830. doi: 10.1016/j.tmaid.2020.101830. Epub 2020 Aug 2.
8
COVID-19: A Worldwide, Zoonotic, Pandemic Outbreak.新型冠状病毒肺炎：一场全球性的人畜共患病大流行疫情。
Altern Ther Health Med. 2020 Aug;26(S2):56-64.
9
COVID-19 Highlights the Need for More Effective Wildlife Trade Legislation.新冠疫情凸显出更有效的野生物贸易立法的必要性。
Trends Ecol Evol. 2020 Dec;35(12):1052-1055. doi: 10.1016/j.tree.2020.10.001. Epub 2020 Oct 7.
10
Correlates of Protection, Thresholds of Protection, and Immunobridging among Persons with SARS-CoV-2 Infection.SARS-CoV-2 感染者的保护相关性、保护阈值和免疫桥接。
Emerg Infect Dis. 2023 Feb;29(2):381-388. doi: 10.3201/eid2902.221422.
引用本文的文献
1
Bioinformatic Tools for Studying the Cellular Immune Response to SARS-CoV-2, Vaccine Efficacy, and Future Pandemics at the Global Population Level.用于在全球人群层面研究针对SARS-CoV-2的细胞免疫反应、疫苗效力及未来大流行的生物信息学工具。
Int J Mol Sci. 2024 Dec 16;25(24):13477. doi: 10.3390/ijms252413477.
本文引用的文献
1
Prediction of Conserved HLA Class I and Class II Epitopes from SARS-CoV-2 Licensed Vaccines Supports T-Cell Cross-Protection against SARS-CoV-1.从新冠病毒授权疫苗预测保守的 HLA I 类和 II 类表位支持针对 SARS-CoV-1 的 T 细胞交叉保护。
Biomedicines. 2022 Jul 7;10(7):1622. doi: 10.3390/biomedicines10071622.
2
Cross-protective immunity following coronavirus vaccination and coronavirus infection.冠状病毒疫苗接种和感染后的交叉保护免疫。
J Clin Invest. 2021 Dec 15;131(24). doi: 10.1172/JCI151969.
3
Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial.RTS,S/AS01疟疾疫苗在非洲婴幼儿中接种或不接种加强剂量的疗效和安全性：一项3期个体随机对照试验的最终结果
Lancet. 2015 Jul 4;386(9988):31-45. doi: 10.1016/S0140-6736(15)60721-8. Epub 2015 Apr 23.
4
Vaccination and the TAP-independent antigen processing pathways.疫苗接种和 TAP 非依赖的抗原加工途径。
Expert Rev Vaccines. 2013 Sep;12(9):1077-83. doi: 10.1586/14760584.2013.825447.
5
Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates.单体和三聚体重组 SARS 冠状病毒刺突蛋白亚单位疫苗候选物的免疫原性和保护效力。
Viral Immunol. 2013 Apr;26(2):126-32. doi: 10.1089/vim.2012.0076.
6
A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial.一种非典DNA疫苗在一项I期临床试验中，在健康成年人中诱导出中和抗体和细胞免疫反应。
Vaccine. 2008 Nov 25;26(50):6338-43. doi: 10.1016/j.vaccine.2008.09.026. Epub 2008 Sep 26.
7
8
Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design.重组杆状病毒表达的严重急性呼吸综合征冠状病毒刺突蛋白的抗原性和免疫原性特征：对疫苗设计的启示
J Virol. 2006 Jun;80(12):5757-67. doi: 10.1128/JVI.00083-06.
9
Trial watch: SARS vaccine enters Phase I trials.试验观察：非典疫苗进入一期试验。
Expert Rev Vaccines. 2004 Aug;3(4):386.
10
Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice.减毒痘苗病毒表达的严重急性呼吸综合征冠状病毒刺突蛋白对小鼠具有保护性免疫作用。
Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6641-6. doi: 10.1073/pnas.0401939101. Epub 2004 Apr 19.
Zotero 插件